Login to Your Account

Orphan Disease Firm Hyperion Files for Potential $57M IPO

By Jennifer Boggs
Managing Editor

Monday, April 16, 2012

Hyperion Therapeutics Inc. joined the initial public offering (IPO) queue Friday, filing an S-1 aiming to raise as much as $57 million to advance pivotal studies, and possible commercial launch, of lead drug Ravicti (glycerol phenylbutyrate) in two orphan indications: urea cycle disorders (UCD) and hepatic encephalopathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription